SCL
Stepan Company
NYSE · Basic Materials · Chemicals - Specialty · US
$63.01
+1.00%Year over year
Reported trailing growth
- Revenue
- +7.6%
- EBITDA
- -18.3%
- EBIT
- +4.3%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- +57.6%
Forward estimates
Based on analyst estimates
- Revenue
- +8.2%
- EBITDA
- +51.4%
- EPS
- +2829.2%
Three-year CAGR
- Revenue
- -5.6%
- EBITDA
- -10.3%
- EBIT
- -30.6%
- Net income
- -31.7%
- EPS
- -31.8%
- Free cash flow
- -35.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026